2. Segment Information and Concentrations

9 Months Ended

Mar. 31, 2018

Segment Reporting [Abstract]

Segment Information and Concentrations

The Company views its operations as three segments: the manufacture and marketing of standard benchtop laboratory equipment for research in university, hospital and industrial laboratories sold primarily through laboratory equipment distributors and laboratory and pharmacy balances and scales (“Benchtop Laboratory Equipment Operations”), the manufacture and marketing of custom-made catalyst research instruments for universities, government laboratories, and chemical and petrochemical companies sold on a direct basis (“Catalyst Research Instruments Operations”) and the design and marketing of bioprocessing systems and products and related royalty income (“Bioprocessing Systems”).

Segment information is reported as follows:

	Benchtop Laboratory Equipment	Catalyst Research Instruments	Bioprocessing Systems	Corporate And Other	Consolidated
Three Months Ended March 31, 2018:
Revenues	$1,550,700	$110,700	$437,900	$-	$2,099,300
Foreign Sales	620,200	105,400	-	-	725,600
Income (Loss) From Operations	78,200	(74,400)	(87,700)	-	(83,900)
Assets	3,930,600	1,680,800	893,300	853,600	7,358,300
Long-Lived Asset Expenditures	4,500	-	-	-	4,500
Depreciation and Amortization	67,400	(800)	9,400	-	76,000

	Benchtop Laboratory Equipment	Catalyst Research Instruments	Bioprocessing Systems	Corporate And Other	Consolidated
Three Months Ended March 31, 2017:
Revenues	$1,410,800	$359,800	$140,300	$-	$1,910,900
Foreign Sales	611,400	37,100	-	-	648,500
Income (Loss) From Operations	88,900	(82,400)	76,500	-	83,000
Assets	4,170,900	1,822,200	485,700	719,200	7,198,000
Long-Lived Asset Expenditures	4,600	-	7,000	-	11,600
Depreciation and Amortization	73,500	1,600	12,000	-	87,100

Approximately 53% and 54% of net benchtop laboratory equipment sales (39% and 40% of total revenues) for the three month periods ended March 31, 2018 and 2017, respectively, were derived from the Company’s main product, the Vortex-Genie 2 mixer, excluding accessories.

Approximately 21% of total benchtop laboratory equipment sales (16% of total revenues) were derived from the Torbal Scales Division for both the three months ended March 31, 2018 and 2017 respectively.

For the three months ended March 31, 2018 and 2017, respectively, two customers accounted in the aggregate for approximately 17% and 15% of net sales of the Benchtop Laboratory Equipment Operations (13% and 11% of the Company’s total revenues).

Sales of catalyst research instruments generally comprise a few very large orders averaging approximately $50,000 per order to a limited number of customers, who differ from order to order. Sales to two and two different customers during the three months ended March 31, 2018 and 2017, accounted for approximately 89% and 76% of the Catalyst Research Instrument Operations’ revenues and 5% and 14% of the Company’s total revenues, respectively. 

	Benchtop Laboratory Equipment	Catalyst Research Instruments	Bioprocessing Systems	Corporate And Other	Consolidated
Nine Months Ended March 31, 2018:
Revenues	$4,436,300	$293,000	$543,300	$-	$5,272,600
Foreign Sales	1,937,800	114,400	-	-	2,052,200
Income (Loss) From Operations	106,300	(361,900)	(124,900)	-	(380,500)
Assets	3,930,600	1,680,800	893,300	853,600	7,358,300
Long-Lived Asset Expenditures	69,700	1,900	2,500	-	74,100
Depreciation and Amortization	199,300	2,700	28,100	-	230,100

	Benchtop Laboratory Equipment	Catalyst Research Instruments	Bioprocessing Systems	Corporate And Other	Consolidated
Nine Months Ended March 31, 2017:
Revenues	$4,334,400	$1,629,400	$190,000	$-	$6,153,800
Foreign Sales	1,924,400	52,200	-	-	1,976,600
Income (Loss) From Operations	252,900	(197,400)	9,100	-	64,600
Assets	4,170,900	1,822,200	485,700	719,200	7,198,000
Long-Lived Asset Expenditures	18,200	-	12,800	-	31,000
Depreciation and Amortization	226,900	12,600	37,000	-	276,500

Approximately 51% and 53% of net benchtop laboratory equipment sales (43% and 37% of total revenues) for the nine month periods ended March 31, 2018 and 2017, respectively, were derived from the Company’s main product, the Vortex-Genie 2 mixer, excluding accessories.

Approximately 22% and 23% of total benchtop laboratory equipment sales (19% and 16% of total revenues) were derived from the Torbal Scales Division for the nine months ended March 31, 2018 and 2017, respectively. For the nine months ended March 31, 2018 and 2017, respectively, two customers accounted in the aggregate for approximately 16% of net sales of the Benchtop Laboratory Equipment Operations (14% and 11% of the Company’s total revenues).

Sales of catalyst research instruments generally comprise a few very large orders averaging approximately $50,000 per order to a limited number of customers, who differ from order to order. Sales to three and four customers during the nine months ended March 31, 2018 and 2017, accounted for approximately 79% and 92% of the Catalyst Research Instrument Operations’ revenues and 4% and 24% of the Company’s total revenues, respectively.